FGF21 and metabolic dysfunction-associated steatohepatitis: A 24-week phase 2b clinical trial evaluating the Fc-conjugated FGF21 analog efruxifermin (AKR-001) indicated significant improvements in NAS and fibrosis stage in patients with MASH with fibrosis stage F2–F3 compared with placebo [8].